Despite the importance of accurate assessment for low-density lipoprotein cholesterol (LDL-C), the Friedewald formula has primarily been used as a cost-effective method to estimate LDL-C when triglycerides are less than 400 mg/dL. In a recent study, an alternative to the formula was proposed to improve estimation of LDL-C. We evaluated the performance of the novel method versus the Friedewald formula using a sample of 5,642 Korean adults with LDL-C measured by an enzymatic homogeneous assay (LDL-CD). Friedewald LDL-C (LDL-CF) was estimated using a fixed factor of 5 for the ratio of triglycerides to very-low-density lipoprotein cholesterol (TG:VLDL-C ratio). However, the novel LDL-C (LDL-CN) estimates were calculated using the N-strata-specific median TG:VLDL-C ratios, LDL-C5 and LDL-C25 from respective ratios derived from our data set, and LDL-C180 from the 180-cell table reported by the original study. Compared with LDL-CF, each LDL-CN estimate exhibited a significantly higher overall concordance in the NCEP-ATP III guideline classification with LDL-CD (p< 0.001 for each comparison). Overall concordance was 78.2% for LDL-CF, 81.6% for LDL-C5, 82.3% for LDL-C25, and 82.0% for LDL-C180. Compared to LDL-C5, LDL-C25 significantly but slightly improved overall concordance (p = 0.008). LDL-C25 and LDL-C180 provided almost the same overall concordance; however, LDL-C180 achieved superior improvement in classifying LDL-C < 70 mg/dL compared to the other estimates. In subjects with triglycerides of 200 to 399 mg/dL, each LDL-CN estimate showed a significantly higher concordance than that of LDL-CF (p< 0.001 for each comparison). The novel method offers a significant improvement in LDL-C estimation when compared with the Friedewald formula. However, it requires further modification and validation considering the racial differences as well as the specific character of the applied measuring method.
Citation: Lee J, Jang S, Son H (2016) Validation of the Martin Method for Estimating Low-Density Lipoprotein Cholesterol Levels in Korean Adults: Findings from the Korea National Health and Nutrition Examination Survey, 2009-2011. PLoS ONE 11(1): e0148147. doi:10.1371/journal.pone.0148147
Editor: Alberto G. Passi, University of Insubria, ITALY
Received: September 3, 2015; Accepted: January 13, 2016; Published: January 29, 2016
Copyright: © 2016 Lee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files. Additional data are available from the https://knhanes.cdc.go.kr/knhanes/index.do.
Funding: This research was supported by the 2014 Hallym University Research Fund (HRF-201407-007). The fund provided support in salaries for one author (J. Lee). The University had no additional role regarding the study design, data collection, data analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Because low-density lipoprotein cholesterol (LDL-C) is a major modifiable risk factor for cardiovascular disease (CVD) , its accurate assessment is important for therapeutic decisions. In routine clinical practice worldwide, it is typically calculated using the Friedewald formula . In the Korea National Health Screening Program (KNHSP), LDL-C is calculated but not directly measured when triglyceride levels are lower than 400 mg/dL. Of 11,380,246 participants who examined their triglyceride levels in the 2013 KNHSP, there were 11,143,810 persons (98%) with triglyceride levels under 400 mg/dL , implying that LDL-C was directly measured for only 2% of the participants. From the outset, the formula’s inaccuracies at triglyceride levels ≥400 mg/dL were recognized by Friedewald et al. . However, even when triglyceride levels are under 400 mg/dL, a number of studies have suggested that LDL-C estimates by the formula (LDL-CF) underestimate LDL-C and thus misclassify CVC risk [5–8], particularly in individuals with high levels of triglycerides [5–7] and LDL-C less than 70 mg/dL .
In a recent study by Martin et al. , an alternative to the Friedewald formula was proposed to improve estimation of LDL-C at triglyceride levels under 400 mg/dL. The Friedewald equation calculates LDL-C as LDL-CF = [total cholesterol]–[high-density lipoprotein cholesterol (HDL-C)]–[triglycerides / 5], where the final term is the estimate of very-low-density lipoprotein cholesterol (VLDL-C). This equation therefore uses a fixed factor of 5 for the ratio of triglycerides to VLDL-C (TG:VLDL-C); however, the Martin equation applies an adjustable factor determined as the N-strata-specific median TG:VLDL-C ratio based on triglyceride and non-HDL-C concentrations to estimate the novel LDL-C (LDL-CN). Compared with LDL-CF, LDL-CN was reported to be closer to directly measured LDL-C (LDL-CD) and improved concordance in guideline risk classification with LDL-CD, especially at LDL-C less than 70 mg/dL.
For adoption of the novel method, external validation is required in independent populations based on various races and the use of other laboratory techniques. Martin et al.  derived the strata-specific TG:VLDL-C ratios using a large cohort of United States patients with LDL-C measured by the vertical auto profile (VAP) method. To our knowledge, none have validated the Martin equation in a Korean population. We therefore evaluated the performance of the LDL-CN estimation method using an independent sample, nationally representative data from the Korea National Health and Nutrition Examination Survey (KNHANES) conducted from 2009 through 2011, in which LDL-C was directly measured by an enzymatic homogenous assay.
Materials and Methods
This study was reviewed and approved by the Kangwon National University Hospital’s institutional review board (KNUH-2015-07-012). The Korea center of Disease Control and Prevention received the informed consent from all participants. The data are publicly available in website [https://knhanes.cdc.go.kr/knhanes/index.do].
This study was performed using data from the 2009–2011 KNHANES[10, 11]. The KNHANES is a nationwide, population-based, cross-sectional survey conducted by the Korean Center for Disease Control and Prevention since 1998. This survey used a stratified, multistage, clustered probability sampling method to select a representative sample of the non-institutional, civilian Korean population. All participants in this survey provided written informed consent.
The number of KNHANES participants was 10,533 in 2009; 8,958 in 2010; and 8,518 in 2011. Among those who participated in the survey, this study included 5,790 adults aged 20 years and older who completed examination of total cholesterol, HDL-C, triglycerides, and LDL-CD. Additionally, 198 subjects with triglyceride levels of 400 mg/dL and higher were excluded, leaving 5,642 subjects (2,723 males and 2,919 females) for the main analysis. The number of subjects by year was as follows: 1,881 in 2009; 1,867 in 2010; and 1,894 in 2011.
Measurements and Estimations
Blood samples were drawn from the antecubital vein of each subject the morning after fasting for at least 8 hours. Serum lipid concentrations were directly measured by an enzymatic method using an automated analyzer (Hitachi Automatic Analyzer 7600, Hitachi, Tokyo, Japan), including measurements of total cholesterol (Pureauto S CHO-N; Sekisui Medical, Tokyo, Japan), HDL-C (Cholestest N HDL; Sekisui Medical), and triglycerides (Pureauto S TG-N; Sekisui Medical). Serum LDL-C concentrations (LDL-CD) were directly measured using an enzymatic homogenous assay with Cholestest-LDL (Sekisui Medical). Non-HDL-C was calculated by subtracting HDL-C from total cholesterol. VLDL-C was calculated using the following subtraction equation: VLDL-C = [non-HDL-C]–[LDL-CD].
LDL-CF was estimated as [non-HDL-C]–[triglycerides / 5] . LDL-C180 was calculated as [non-HDL-C]–[triglycerides / AF], where AF is an adjustable factor in the 180-cell table described by Martin et al. . In addition, two LDL-CN estimates were calculated using strata-specific TG:VLDL-C ratios derived from our data set: LDL-C5 based on 5 strata of triglycerides and LDL-C25 based on 25 strata of triglyceride and non-HDL-C levels.
The data were analyzed using SPSS for Windows (version 21.0; SPSS Inc., Chicago, IL, USA). All statistical outcomes were based on two-sided tests, and a p-value less than 0.05 was considered statistically significant. Data are summarized as median and range for continuous variables, and frequency and percentage for categorical variables. To compare the two triglyceride groups (subjects with triglycerides ≤ 400 mg/dL and those with > 400 mg/dL), the median test was used for continuous variables, and Fisher’s exact test was used for categorical variables. Multiple regression analysis was performed to investigate the extent to which VLDL-C was explained by triglycerides, non-HDL-C, HDL-C, and age.
When triglyceride levels were lower than 400 mg/dL, the Wilcoxon signed rank test was conducted to examine the difference between each estimated LDL-C and LDL-CD value, and to determine whether LDL-CN estimates more closely approximated LDL-CD compared with LDL-CF. The median test was used to compare the median TG:VLDL-C ratios among five strata based on triglyceride levels. One-way analysis of variance (ANOVA) was performed for multiple comparison of the mean VLDL-C: TG ratios among the triglyceride strata.
Directly measured and estimated LDL-C values were classified according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) guideline cutoffs of 70, 100, 130, 160, and 190 mg/dL. Concordance in classification between LDL-C estimates and LDL-CD was examined through cross-tabulations by LDL-C categories in subjects with triglycerides lower than 400 mg/dL. McNemar’s exact test for correlated proportions was performed to compare overall concordance between LDL-C estimates.
Table 1 shows sex, age, and lipid characteristics of the sample population overall and by triglyceride group. Of 5,790 samples, only 148 subjects (2.6%) had triglyceride levels of 400 mg/dL and higher. All variables except for median age were significantly different between triglyceride groups. 5,642 subjects with triglyceride levels under 400 mg/dL were mostly middle-aged [median, 45 years; interquartile range (IQR), 33–57 years] and evenly distributed by sex [48.3% male]. In this triglyceride group, the median TG:VLDL-C ratio was 4.9, the IQR was 3.7–6.1, the 5th to 95th percentile was 2.3 to 8.4, the 1st to 99th percentile was 1.6 to 11.5, and the full range was 0.6 to 285.7.
Fig 1 illustrates the relationship between triglyceride and VLDL-C values. When triglyceride levels are lower than 400 mg/dL, triglycerides explained 62.3% of the variance in VLDL-C. Adding non-HDL-C as an independent variable, as shown in Model 1 of Table 2, the explained proportion of the variance increased slightly to 64.4%. In this model, triglycerides had a partial R2 value of (0.733)2 = 0.537, whereas that of non-HDL-C was (0.263)2 = 0.069, implying that triglycerides accounted for 7.8 times more of the variance than did non-HDL-C. Controlling for non-HDL-C, HDL-C, and age in Model 2 of Table 2, triglycerides and VLDL-C showed a relatively strong relationship (partial R = 0.748) compared to the other independent variables.
The dark right-upward line represents the values of triglycerides divided by 5, the estimates of VLDL-C used in the Friedewald formula. If the true VLDL-C value is greater than the triglycerides/5 value (dots above the line), then the Friedewald equation will tend to underestimate VLDL-C, and vice versa if the true VLDL-C is less than the triglycerides/5 (dots below the line). Overall, the Friedewald formula showed a tendency to overestimate VLDL-C and thus underestimate LDL-C as triglyceride levels increased. The broken line displays the fitted regression of triglycerides on VLDL-C when triglyceride levels are lower than 400 mg/dL.
For stratification, we first used only triglycerides and then added non-HDL-C to capture each performance of the two parameters in improving LDL-C estimation. Based on strata of triglycerides, the 5-cell table is shown in Table 3. The median TG:VLDL-C ratio was significantly different among triglyceride groups (p< 0.001) and increased as triglyceride levels went up. The median TG:VLDL-C ratio of each triglyceride strata ranged from 2.71 to 6.21.The 25-cell table, based on strata of triglyceride and non-HDL-C values, is shown in Table 4. For the same triglyceride group, the median TG:VLDL-C ratio generally decreased as non-HDL-C levels increased.
To generate LDL-CN estimates, the strata-specific median TG: VLDL-C ratios were applied in subjects of our data set with triglyceride levels under 400 mg/dL. That is, the 5-cell table (Table 3) was used for LDL-C5, the 25-cell table (Table 4) for LDL-C25, and the 180-cell table described by Martin et al.  for LDL-C180. Comparing each estimated LDL-C and LDL-CD value by the 5 strata of triglyceride levels using the Wilcoxon signed rank test (see S1 through S4 Tables), LDL-CF significantly overestimated LDL-CD at triglyceride levels under 100 mg/dL (p< 0.001) while LDL-CF underestimated LDL-CD at triglyceride levels of 100–399 mg/dL (p< 0.001). LDL-C5 and LDL-C25 did not significantly underestimate or overestimate LDL-CD at any triglyceride level; however, LDL-C180 significantly overestimated LDL-CD at all triglyceride levels (p< 0.001). At triglyceride levels under 400 mg/dL, LDL-CN estimates were closer overall to LDL-CD than LDL-CF estimates (p < 0.001 for each comparison, see S5 Table). The median for (LDL-CF)–(LDL-CD) was 0.6 mg/dL (IQR, -5.1 to 5.7; 5th-95th percentile, -15.2 to 13.5). Examining LDL-CN−LDL-CD, the median was 0.0 mg/dL (IQR, -4.2 to 4.5; 5th-95th percentile, -9.9 to 13.2) for LDL-C5, 0.0 mg/dL (IQR, -4.1 to 4.4; 5th-95th percentile, -10.0 to 12.3) for LDL-C25, and 1.5 mg/dL (IQR, -2.5 to 5.9; 5th-95th percentile, -8.1 to 14.0) for LDL-C180.
Table 5 shows concordances in the NCEP-ATP III guideline classification between LDL-C estimates and LDL-CD and between LDL-C estimates when triglyceride levels are lower than 400 mg/dL. Compared with LDL-CF, LDL-CN estimates exhibited a significantly higher overall concordance (p < 0.001 for each comparison). In subjects with triglyceride levels of 200 to 399 mg/dL, LDL-CN estimates showed significantly higher concordances than those of LDL-CF estimates (p< 0.001 for each comparison). In particular, LDL-C25 provided a significantly higher concordance than LDL-C180 (p = 0.026). In other triglyceride categories, LDL-CN estimates incrementally improved concordance compared with LDL-CF.
Fig 2 shows overall discordance in the NCEP-ATP III guideline classification by LDL-C estimate when triglyceride levels are lower than 400 mg/dL. Within the misclassified subjects, there were two groups: those who were classified in a lower category and those who were classified in a higher category compared with their LDL-CD category (see S6 Table). When we referred to the former as underestimated and the latter as overestimated in their LDL-C categories, the number of underestimated subjects was similar to that of the overestimated subjects for LDL-CF, LDL-C5, and LDL-C25: 623 underestimated subjects (11.0%) versus 605 overestimated subjects (10.7%) for LDL-CF; 509 subjects (9.0%) versus 529 subjects (9.4%) for LDL-C5; and 495 subjects (8.8%) versus 506 subjects (9.0%) for LDL-C25. For LDL-C180, however, the number of overestimated subjects was about two times larger than that of the underestimated subjects; 672 subjects (11.9%) were classified in a higher category, but 342 subjects (6.1%) were classified in a lower category.
We compared the performance of the novel method and the Friedewald formula on estimating LDL-C using a sample of 5,642 Korean adults with LDL-C measured by the enzymatic homogenous assay. As novel estimates, LDL-C5 and LDL-C25 were calculated using the strata-specific median TG:VLDL-C ratios derived from our data set, together with LDL-C180 using the 180-cell table described by Martin et al. . Each of these LDL-CN estimates was significantly more similar to LDL-CD than LDL-CF in subjects with triglyceride levels lower than 400 mg/dL (p< 0.001 for each comparison).
To estimate LDL-C, the novel method uses an adjustable factor for the TG:VLDL-C ratio according to triglyceride and non-HDL-C levels, whereas the Friedewald equation applies a fixed factor of 5. Some previous studies [12–14] have attempted to determine an optimal fixed factor. For example, DeLong et al.  and Puavilai et al.  suggested a higher fixed factor of 6 instead of 5 while Hata and Nakajima  proposed a lower fixed factor of 4. However, the overall median TG:VLDL-C ratio of 4.9 in our sample is closer to the original Friedewald factor of 5. In contrast, McNamara et al.  found that the optimal factor varied by triglyceride level and suggested different factors based on triglyceride values: 4 for triglyceride levels ≤50 mg/dL, 4.5 for levels of 51–200 mg/dL, and 5 for levels of 201–400 mg/dL. Compared with the McNamara method, the novel method extends its basis for applying the strata-specific TG:VLDL-C ratios from triglycerides to non-HDL-C values. Considering the broken line in Fig 1, the novel method is assumed to be useful for the more correct estimation of LDL-C in Korean people.
In this study, we first generated LDL-C5 based on only triglyceride strata. The median TG:VLDL-C ratio was significantly different among triglyceride strata (p< 0.001) and increased as triglyceride levels went up (Table 3), which is similar to the findings of McNamara et al. . Next, we generated LDL-C25 based on the 25 strata of triglyceride and non-HDL-C levels. For the same triglyceride group, the median TG:VLDL-C ratio roughly decreased as non-HDL-C levels increased (Table 4), as in the 180-cell table of Martin et al. . However, we were able to observe a difference between the median TG: VLDL-C ratio of LDL-C25 and that of LDL-C180 at triglyceride levels less than 50mg/dL, with ranges from 2.1 to 2.8 versus ranges from 3.1 to 3.5 for LDL-C25 and LDL-C180, respectively. Wang et al.  suggested that, similar to high TG levels, low TG levels affect LDL-CF, resulting in overestimation. They attributed this to a low-fat, low-protein diet. Considering the carbohydrate-oriented dietary life pattern of Koreans, their lipid profile may differ from that of Westerners.
The majority of previous studies have suggested that the Friedewald formula underestimates directly measured LDL-C [5–8]. In our sample, LDL-CF significantly underestimated LDL-CD at levels of 100–399 mg/dL, but significantly overestimated LDL-CD at triglyceride levels under 100 mg/dL. On the other hand, LDL-C180 significantly overestimated LDL-CD for the entire triglyceride range.LDL-C5 and LDL-C25 did not show any tendency of over/underestimation.
Compared with LDL-CF, each of the LDL-CN estimates exhibited a significantly higher overall concordance with LDL-CD in the NCEP-ATP III guideline classification (p< 0.001 for each comparison). Overall concordance was 78.2% for LDL-CF, 81.6% for LDL-C5, 82.3% for LDL-C25, and 82.0% for LDL-C180 (Table 5). Compared with LDL-C5, LDL-C25 significantly improved overall concordance (p = 0.008). LDL-C25 and LDL-C180 provided almost the same overall concordance. In comparison to the overall concordance of 85.4% for LDL-CF versus 91.7% for LDL-C180 (p< 0.001) reported by Martin et al. , LDL-CF and LDL-C180 in our sample have shown relatively low overall concordance with LDL-CD. Meeusen et al.  found that overall concordance was similar to that of our results as 76.9% [95% CI, 75.2–79.4] for LDL-CF versus 77.7% [95% CI, 76.0–79.6] for LDL-C180.In our sample, however, LDL-C180 has shown significantly higher overall concordance than LDL-CF. Compared with LDL-CF by LDL-C category, LDL-C5 was more concordant only when LDL-C was under 160 mg/L; however, LDL-C25and LDL-C180were more concordant in all LDL-C categories. When LDL-C was lower than 70 mg/dL, as reported by Martin et al. , LDL-C180 improved greatly in concordance compared with LDL-CF.This was particularly apparent in subjects with high triglyceride levels (see S1 Fig). In subjects with triglyceride levels of 200 to 399 mg/dL, LDL-C25 provided a significantly higher concordance than LDL-CF (p = 0.001) and LDL-C180 (p = 0.026).
However, a point of precaution is that while there may be high concordance in a special stratum, the specific method in that stratum may not be the most appropriate method. LDL-C180 showed high concordance of 84.1% for LDL-C less than 70mg/dL, but in reality, 129 out of 361 subjects with LDL-C less than 70mg/dL showed overestimation (see Table 5, S6 Table). The overall concordance of 82.3% for LDL-C25 was the highest. Compared to the Friedewald formula, it showed higher concordance at all LDL-C levels, and the 78.8% concordance at LDL-C less than 70mg/dL was lower than that of LDL-C180, but still accurately categorized more subjects (279 individuals, Table 5). The purpose of the clinical screening test is to accurately diagnose a greater number of patients and apply appropriate treatments. Thus, simply analyzing the concordance can lead to erroneous results. Instead, multiple points must be considered, such as each method’s trend of diagnosis, sensitivity, specificity, and perceived ease of use in actual application, in addition to the concordance.
Overall, LDL-C180 showed approximately two times as much overestimation as underestimation (Fig 2). This result can be interpreted in two folds. First, this overestimation might be exaggerated because of problems with the method for the direct LDL measurement. Serum LDL-C concentrations in our study were directly measured using the enzymatic homogeneous assay by Sekisui Medical instead of the gold standard β-quantification reference method used by Martin et al. . β-quantification consistently captures all three elements of LDL by its standard definition: true LDL plus IDL plus Lp(a). In contrast, chemical homogeneous assays directly measuring LDL-C does not consistently capture the three elements, subsequently being prone to LDL-C underestimation . The overestimation observed in our study, therefore, may be actually due to the Sekisui assay missing some elements of LDL-C.
Another possible explanation is that the overestimation of LDL-C by LDL-C180 can be attributed to racial differences and related difference in dietary patterns. This could be postulated to impact TG:VLDL-C ratio. We have partly identified the differences in the median TG:VLDL-C ratio by triglyceride and non-HDL-C strata between Korean and American. For example, the median TG:VLDL-C ratio of subjects with TG of < 50 mg/dL and non-HDL-C of <100 mg/dL was 2.7 in our study versus 3.5 in Martin et al.’s study . However, we calculated VLDL-C as non-HDL-C minus LDL-CD, so it could be also affected by direct measuring method of LDL-C.
The application of strata-specific TG:VLDL-C ratios, like Martin’s novel method, can estimate a more accurate LDL-C of LDL-C levels under 70mg/dL than the Friedewald formula. In 2012, there were approximately 15 million target subjects for the Korea National Health Screening Program (KNHSP), 11.5 million of those that were actually screened, and approximately 865,000 of total screened subjects in the LDL-C<70mg/dL category . In addition to subjects with TG>400mg/dL, direct measurement is needed for precise detection of the subjects with LDL-C<70mg/dL, rather than the use of Friedewald formula. However, the use of LDL-C25 or LDL-C180 allows for even more accurate estimation of LDL-C as well as the lowering of testing costs.
One of the limitations of this study is that the direct measurement method of LDL-C is not the same as β–quantification used by Martin et al. . It has been reported that liquid selective detergent method, such as Sekisui Medical, revealed a negative deviation from the Friedewald’s equation and β-quantification in hypercholesterolemia [19–21]. Considering this effect for higher levels of LDL-C categories, the overestimation of LDL-C180 may be somewhat exaggerated than the actual value, although our study population mainly consists of normal healthy subjects. Miller et al. have compared and analyzed various homogenous assays with β-quantification . In their study, Sekisui assay fulfilled the NCEP total error goal in non-diseased subjects. Other studies also have reported that some homogenous assays, including Sekisui Medical, showed a good correlation with Friedewald equation or β-quantification for common disease and healthy subjects with satisfactory precision. The authors suggested that homogenous assays could be used in epidemiologic studies, both in fasting and non-fasting samples [23,24].
Another limitation of this study is that VLDL was not directly measured, but rather it was calculated using the formula TC—HDL-C—LDL-C. In this calculation, concentrations of chylomicron, IDL-C, and others were not considered. Thus, cases such as a high level of chylomicron could increasingly lead to erroneous readings. However, the relative proportion of chylomicron in total cholesterol is very small, and all subjects were under strict eight hour fasting conditions, so the likelihood of error in this area was likely minimized as much as possible.
In conclusion, Martin’s novel method, which uses the strata-specific TG:VLDL-C ratio, provides a more accurate LDL-C estimation in Koreans in comparison to the Friedewald formula, which uses the fixed TG:VLDL-C ratio. Moreover, the former showed a higher concordance in categorization based on NCEP-ATP classification. However, LDL-C180 based on Martin’s data, when applied to Koreans, resulted in excessive overestimation and thus may indicate racial differences in readings, but the result should be judged with considering the measuring method. It requires further investigations using the same measuring method for LDL-C. LDL-C25 showed the highest overall concordance of 82.3%. Most of all, in comparison to the Friedewald method, LDL-C25 showed higher concordance in all levels and no bias in diagnostic tendencies. Therefore, it is worth considering Martin’s novel method as a trustworthy and economical method for the estimation of LDL-C among Koreans. However, the level of racial specificity of this method as well as the specific character of the applied measuring method should be considered, and the method requires further modification and validation using strata-specific TG:VLDL-C ratios derived from data specific to Koreans.
S1 Fig. Concordance of direct measurement with Friedewald and novel estimates in classifying LDL-C lower than 70 mg/dL by triglyceride strata.
LDL-C indicates low-density lipoprotein cholesterol; LDL-CF, Friedewald LDL-C; LDL-C5, 5-cell method LDL-C; LDL-C25, 25-cell method LDL-C; LDL-C180, 180-cell method LDL-C (Martin et al. ).
S1 Table. Results ofthe Wilcoxon signed ranks test for the median score difference between LDL-CF and LDL-CD values (LDL-CF—LDL-CD) by TG levels.
LDL-C indicates low-density lipoprotein cholesterol; LDL-CF, Friedewald LDL-C; LDL-CD, LDL-C measured by the enzymatic homogeneous assay; TG, triglycerides. Under the null hypothesis of no difference, the sum of the ranks relating to the positive and negative difference should be the same. If SP > SN, where SP = the sum of the positive ranks and SN = the sum of the negative ranks, then LDL-CF overestimates LDL-CD; if SN > SP, then LDL-CF underestimates LDL-CD.
S2 Table. Results of the Wilcoxon signed ranks test for the median score difference between LDL-C5 and LDL-CD values (LDL-C5—LDL-CD) by TG levels.
LDL-C indicates low-density lipoprotein cholesterol; LDL-C5, 5-cell method LDL-C; LDL-CD, LDL-C measured by the enzymatic homogeneous assay; TG, triglycerides. Under the null hypothesis of no difference, the sum of the ranks relating to the positive and negative difference should be the same. If SP > SN, where SP = the sum of the positive ranks and SN = the sum of the negative ranks, then LDL-C5 overestimates LDL-CD; if SN > SP, then LDL-C5 underestimates LDL-CD.
S3 Table. Results ofthe Wilcoxon signed ranks test for the median score difference between LDL-C25 and LDL-CD values (LDL-C25—LDL-CD) by TG levels.
LDL-C indicates low-density lipoprotein cholesterol; LDL-C25, 25-cell method LDL-C; LDL-CD, LDL-C measured by the enzymatic homogeneous assay; TG, triglycerides. Under the null hypothesis of no difference, the sum of the ranks relating to the positive and negative difference should be the same. If SP > SN, where SP = the sum of the positive ranks and SN = the sum of the negative ranks, then LDL-C25 overestimates LDL-CD; if SN > SP, then LDL-C25 underestimates LDL-CD.
S4 Table. Results ofthe Wilcoxon signed ranks test for the median score difference between LDL-C180 and LDL-CD values (LDL-C180—LDL-CD) by TG levels.
LDL-C indicates low-density lipoprotein cholesterol; LDL-C180, 180-cell method LDL-C (Martin et al. ); LDL-CD, LDL-C measured by the enzymatic homogeneous assay; TG, triglycerides. Under the null hypothesis of no difference, the sum of the ranks relating to the positive and negative difference should be the same. If SP > SN, where SP = the sum of the positive ranks and SN = the sum of the negative ranks, then LDL-C180 overestimates LDL-CD; if SN > SP, then LDL-C180 underestimates LDL-CD.
S5 Table. Results of the Wilcoxon signed ranks test for the median score differences between | LDL-CF-LDL-CD| and | LDL-CN-LDL-CD|values.
LDL-C indicates low-density lipoprotein cholesterol; LDL-CF, Friedewald LDL-C; LDL-C5, 5-cell method LDL-C; LDL-C25, 25-cell method LDL-C; LDL-C180, 180-cell method LDL-C (Martin et al. ); LDL-CD, LDL-C measured by the enzymatic homogeneous assay. Under the null hypothesis of no difference, the sum of the ranks relating to the positive and negative difference should be the same. If SP > SN, where SP = the sum of the positive ranks and SN = the sum of the negative ranks, then LDL-CN more closely approximated LDL-CD; if SN > SP, then LDL-CF more closely approximated LDL-CD.
S6 Table. Concordance of the NCEP-ATP III guideline classification between LDL-CD and LDL-C estimates when triglycerides are lower than 400 mg/dL.
LDL-C indicates low-density lipoprotein cholesterol; LDL-CD, LDL-C measured by the enzymatic homogeneous assay; LDL-CF, Friedewald LDL-C; LDL-C5, 5-cell method LDL-C; LDL-C25, 25-cell method LDL-C; LDL-C180, 180-cell method LDL-C (Martin et al. ).
S7 Table. Results of McNemar’s exact test for the comparison of overall concordance rates between LDL-CF and each LDL-CN estimate when triglycerides are lower than 400 mg/dL.
LDL-C indicates low-density lipoprotein cholesterol; LDL-CF, Friedewald LDL-C; LDL-C5, 5-cell method LDL-C; LDL-C25, 25-cell method LDL-C; LDL-C180, 180-cell method LDL-C (Martin et al. ).
S8 Table. Results of McNemar’s exact test for the comparison of concordance rates between LDL-CF and each LDL-CN estimate by triglyceride levels.
LDL-C indicates low-density lipoprotein cholesterol; LDL-CF, Friedewald LDL-C; LDL-C5, 5-cell method LDL-C; LDL-C25, 25-cell method LDL-C; LDL-C180, 180-cell method LDL-C (Martin et al. ); TG, triglycerides.
The authors are grateful to the editor, Alberto G Passi, two anonymous referees at PLOS ONE, as well as Hyesu Lee, OhkhyunRyu, and Yongsup Kim. The authors also thank seminar participants at Hallym University, Kangwon National University, and Korea Advanced Institute of Science and Technology.
Conceived and designed the experiments: JL HS. Performed the experiments: SJ HS. Analyzed the data: JL HS SJ. Contributed reagents/materials/analysis tools: JL SJ. Wrote the paper: HS JL SJ. Interpretation of the results: JL HS. Critical revision of manuscript for important intellectual content: JL SJ HS.
- 1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285: 2486–97. pmid:11368702 doi: 10.1001/jama.285.19.2486
- 2. Stein EA. Measuring LDL cholesterol: for old and new calculations, is there an optimal formula? Chin Chem 2014;60: 1466–68. doi: 10.1373/clinchem.2014.232793
- 3. National Health Insurance Service. 2013 National Health Screening Statistical Yearbook. 2014.
- 4. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Chin Chem 1972;18: 499–502.
- 5. Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogenous assays versus calculation. Clin Chem 2002;48: 236–54. pmid:11805004
- 6. Martin SS, Blaha MJ, Elshazly MB, Brinton EA, Toth PP, McEvoy JW, et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol 2013;62: 732–9. doi: 10.1016/j.jacc.2013.01.079. pmid:23524048
- 7. Oliveira MJ, van Deventer HE, Bachmann LM, Warnick GR, Nakjima K, Nakamura M, et al. Evaluation of four different equations for calculating LDL-C with eight different direct HDL-C assays. Clin Chem Acta 2013;423: 135–40. doi: 10.1016/j.cca.2013.04.009
- 8. Scharnagl H, Nauck M, Wieland H, März W. The Friedewald formula underestimates LDL cholesterol at low concentrations. ClinChem Lab Med 2001;39: 426–31. doi: 10.1515/cclm.2001.068
- 9. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, et al. Comparison of a novel method vs the Friedewald equation for estimating Low-Density Lipoprotein cholesterol levels from the standard lipid profile. JAMA 2013;310: 2061–8. doi: 10.1001/jama.2013.280532. pmid:24240933
- 10. Korea Centers for Disease Control and Prevention. The Fourth Korea National Health and Nutrition Survey (KNHANES IV). Available: http://knhanes.cdc.go.kr/.
- 11. Korea Centers for Disease Control and Prevention. The Fifth Korea National Health and Nutrition Survey (KNHANES V). Available: http://knhanes.cdc.go.kr/.
- 12. DeLong DM, DeLong ER, Wood PD, Lipppel K, Rikind BM. A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol: the Lipid Research Clinics Prevalence Study. JAMA 1986;256: 2372–7. pmid:3464768 doi: 10.1001/jama.1986.03380170088024
- 13. Puavilai W, Deerochanawong C, Muthapongthavorn N, Srilert P. The accuracy in using modified Friedewald equation to calculate LDL for non-fast triglycerides: A pilot study. J Med Assoc Thai 2009;92: 182–7. pmid:19253792
- 14. Hata Y, Kakajima K. Application of Fridewald’s LDL-cholesterol estimation formula to serum lipids in the Japanese population. Japanese Circulation Journal 1986;12: 1191–1200. doi: 10.1253/jcj.50.1191
- 15. McNamara JR, Cohn JS, Wilson PWF, Schaefer EJ. Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Chin Chem 1990;36: 36–40.
- 16. Wang Teh Y, Wang Thomas S. Low Triglycerides levels affect calculation of Low-Density Lipoprotein Cholesterol values. Archives of Pathology & Laboratory Medicine 2001;125(3): 404–5.
- 17. Meeusen JW, Lueke AJ, Jaffe AS, Saenger AK. Validation of a proposed novel equation for estimating LDL cholesterol. ClinChem 2014;60: 1519–23. doi: 10.1373/clinchem.2014.227710
- 18. National Health Insurance Service. 2012 National Health Screening Statistical Yearbook. 2013
- 19. Yamada K., Tsuji N., Fujita T., Tanaka M., Kuribayashi K., Kobayashi D., et al. Comparison of four direct homogenous methods for the measurement of Low-Density Lipoprotein Cholesterol. Clin Lab 2010; 56: 327–333 pmid:20857897
- 20. Zhang B, Kawachi E, Matsunaga A, Imaizumi S, Noda K., Uehara Y., et al. Reactivity of direct assays for Low-Density Lipoprotein (LDL) Cholesterol toward charge-modified LDL in hypercholesterolemia. Circ J 2012; 76: 2241–2248. pmid:22785328 doi: 10.1253/circj.cj-12-0381
- 21. Yamashita S., Kawase R., Nakaoka H., Nakatani K., Inagaki M., Yuasa-Kawase M., et al. Differential reactivities of four homogeneous assays for LDL-cholesterol in serum to intermediate-density lipoproteins and small dense LDL: Comparisons with the Friedewald equation. Clin Chim Acta2009; 410: 31–38. doi: 10.1016/j.cca.2009.09.010. pmid:19751710
- 22. Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, et al. Seven direct methods for measuring HDL and LDL Cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem 2010; 56(6): 977–986. doi: 10.1373/clinchem.2009.142810. pmid:20378768
- 23. Tanno K., Okamura T., Ohsawa M., Onoda T., Itai K., Sakata K., et al. Comparison of low-density lipoprotein cholesterol concentrations measured by a direct homogeneous assay and by the Friedewald formula in a large community population. Clin Chim Acta 2010; 411: 1774–1780. doi: 10.1016/j.cca.2010.07.034. pmid:20688051
- 24. Miida T., Nishimura K., Okamura T., Hirayama S., Ohmura H., Yoshida H., et al. A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: Comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects. Atherosclerosis 2012; 225: 208–215. doi: 10.1016/j.atherosclerosis.2012.08.022. pmid:22980501